Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

1.7K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.7K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

646
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
646
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

844
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
844
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

748
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
748
Drug Therapy01:28

Drug Therapy

355
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
355

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel methods for the assessment of safety pharmacology and toxicology parameters in anesthetized and ventilated dogs receiving inhaled drugs.

Journal of pharmacological and toxicological methods·2019
Same author

Klein tunnelling and Hartman effect in graphene junctions with proximity exchange field.

Journal of physics. Condensed matter : an Institute of Physics journal·2019
Same author

The Ketogenic Diet: A Solution to Ireland's Obesity Epidemic?

Irish medical journal·2017
Same author

Lasing from active optomechanical resonators.

Nature communications·2014
Same author

The effect of booster vaccination on protective humoral antibodies against dysentery in children.

Journal of bacteriology·2010
Same author

Active immunization of children with Shigella vaccines.

Proceedings [of the] annual meeting. Central Society for Clinical Research (U.S.)·2010
Same journal

Unlocking the potential of electronic health records for research purposes.

Irish medical journal·2026
Same journal

ICU Handover: A Persistent Vulnerability in Critical Care Settings.

Irish medical journal·2026
Same journal

The Sugar-Sweetened Beverage Tax (Sugar Tax): Innovation and Stasis.

Irish medical journal·2026
Same journal

Gastrointestinal trichobezoars presenting as abdominal pain and obstruction - Rapunzel syndrome.

Irish medical journal·2026
Same journal

When Sepsis Kills: A Fatal Cascade of Invasive Group A Streptococcal Sepsis.

Irish medical journal·2026
Same journal

Fulminant Thrombotic Thrombocytopenic Purpura presenting through the FAST Stroke Pathway.

Irish medical journal·2026
See all related articles

Related Experiment Video

Updated: Mar 8, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.8K

Ketamine: Future Treatment For Unresponsive Depression?

M Frere1, J Tepper1

  • 1School of Medicine, National University of Ireland, Galway.

Irish Medical Journal
|January 27, 2017
PubMed
Summary
This summary is machine-generated.

Major Depressive Disorder (MDD) treatment often fails, leading to Treatment-Resistant Depression (TRD). Low-dose ketamine shows promise for swift TRD symptom relief, though further research is needed.

More Related Videos

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

23.0K
Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

677

Related Experiment Videos

Last Updated: Mar 8, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.8K
Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

23.0K
Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

677

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Major Depressive Disorder (MDD) is a leading cause of global disability.
  • Traditional antidepressants (SSRIs, SNRIs) have delayed efficacy and limited success rates.
  • Treatment-Resistant Depression (TRD) affects a significant portion of MDD patients, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To review the emerging therapeutic potential of low-dose intravenous ketamine for Major Depressive Disorder.
  • To highlight ketamine's rapid and effective symptom mitigation in Treatment-Resistant Depression.
  • To acknowledge existing barriers to ketamine's clinical adoption.

Main Methods:

  • Literature review of existing studies on ketamine's efficacy in treating depression.
  • Analysis of current understanding of ketamine's molecular mechanisms in therapeutic contexts.
  • Examination of safety profiles and dependence risks associated with ketamine use.

Main Results:

  • Ketamine demonstrates swift and significant reduction in depressive symptoms, particularly in TRD cases.
  • The precise molecular pathways underlying ketamine's antidepressant effects are still under investigation.
  • Concerns regarding ketamine's safety and potential for abuse present challenges to its widespread prescription.

Conclusions:

  • Low-dose ketamine represents a promising pharmacotherapy for Treatment-Resistant Depression.
  • Further research is crucial to fully elucidate ketamine's mechanisms and optimize its therapeutic application.
  • Addressing safety concerns and regulatory hurdles is essential for integrating ketamine into clinical practice for MDD.